Promotion of Cx26 mutants located in TM4 region for membrane translocation successfully rescued hearing loss

Yan-Jun Zong,^{1†} Xiao-Zhou Liu,^{1†} Xin-Yu Shi,¹ Zheng-Dong Zhao,¹ and Yu Sun^{1,2,3,*}

1 Department of Otorhinolaryngology, Union Hospital, Tongji Medical College,

Huazhong University of Science and Technology, Wuhan 430022, China.

2 Institute of Otorhinolaryngology, Union Hospital, Tongji Medical College,

Huazhong University of Science and Technology, Wuhan 430022, China.

3 Hubei Province Clinic Research Center for Deafness and Vertigo, Wuhan 430022,

China.

* Correspondence: sunyu@hust.edu.cn

[†] These authors contributed equally to this work




Figure S1 Narciclasine promotes the development of cytoskeleton and increases the membrane localization of WT-Cx26 in vitro and in vivo. (A-C) Quantification of the F-actin fluorescence intensity (A), acetylated α -tubulin fluorescence intensity (B), and Cx26 fluorescence intensity on plasma membrane (C) from the control group and Narciclasine-treated group in vitro. (D-G) Quantification of the F-actin fluorescence intensity (D), acetylated α -tubulin fluorescence intensity (E), and the lengths of GJPs on DCs (F) and ISCs (G) from the control group and the Narciclasine-treated group in vivo. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001.




Figure S2 Narciclasine treatment increases membrane localization of Cx30 and Cx26 in DCs in Del-Cx26 mice. (A-B) Immunofluorescence staining of Cx30 (Red), Cx26 (Green), and F-actin (White) in the Del-Cx26 mice (A) and in the Del-Cx26 mice treated with Narciclasine (B). (C-D) Quantification of the lengths of Cx30 GJPs (C) and Cx26 GJPs (D) from the Del-Cx26 mice and the Del-Cx26 mice treated with Narciclasine on DCs at P30. Scale bars: 20 μ m (panels A-B), and 7 μ m (partial enlargement in panels A-B).*P < 0.05, **P < 0.005.

